Table 1 Clinical data and treatment at the time of renal biopsy
From: Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases
| Â | Diagnosis | Clinical data | Treatment | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gender | Blood pressure (mmHg) | sCr (mg/dL) | eGFR (mL/min/1.73m2) | Alb (g/dl) | Tchol (mg/dl) | HbA1c (%) | UPCR (g/gCr) | Duration of DM (years) | RAS inhibitor | DPP-4 inhibitor | Biguanide | SGLT2 inhibitor | SU | Glinide | αGI | Insulin | ||
case 1 | Minor glomerular abnormalitya | female | 90/52 | 0.55 | 102.0 | 4.2 | 210 | 5.3 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
case 2 | Minor glomerular abnormality | female | 100/63 | 0.50 | 115.3 | 4.6 | 170 | 5.4 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
case 3 | Minor glomerular abnormality | female | 110/64 | 0.85 | 62.8 | 4.3 | 156 | 6.0 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
case 4 | ANCA-RNa | female | 122/64 | 2.37 | 17.6 | 3.1 | 258 | 6.0 | 2.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
case 5 | ANCA-RN | female | 110/60 | 2.08 | 20.6 | 3.7 | 199 | 5.6 | 0.6 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
case 6 | ANCA-RN with DPP-4i | male | 125/60 | 1.77 | 32.8 | 3.4 | 170 | 6.6 | 1.7 | 15 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
case 7 | ANCA-RN | female | 160/70 | 0.98 | 42.8 | 3.8 | 210 | 6.7 | 0.4 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
case 8 | FSGSa | female | 120/82 | 1.04 | 50.7 | 3.0 | 224 | 5.2 | 1.6 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
case 9 | FSGS | male | 120/78 | 1.02 | 60.1 | 2.0 | 369 | 5.1 | 6.7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
case 10 | FSGS | male | 142/70 | 0.91 | 72.1 | 1.9 | 379 | 5.7 | 5.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
case 11 | FSGS | male | 122/72 | 0.92 | 76.0 | 4.0 | 170 | 5.1 | 0.4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
case 12 | FSGS | male | 128/74 | 1.94 | 33.6 | 4.7 | 199 | 5.5 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
case 13 | FSGS | female | 122/62 | 1.03 | 48.3 | 4.0 | 217 | 5.3 | 2.8 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
case 14 | FSGS | female | 116/60 | 0.81 | 69.2 | 2.9 | 216 | 5.9 | 7.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
case 15 | Nephrosclerosisa | male | 122/78 | 0.75 | 76.3 | 4.1 | 218 | 5.9 | 0.0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
case 16 | DN w/o DPP-4iab | male | 118/62 | 0.85 | 65.7 | 4.4 | 210 | 6.7 | 0.9 | unknown | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
case 17 | DN w/o DPP-4ib | male | 132/78 | 1.50 | 48.4 | 3.4 | 208 | 6.4 | 5.0 | 20 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
case 18 | DN w/o DPP-4ib | male | 134/84 | 0.77 | 71.2 | 2.1 | 227 | 8.1 | 5.5 | 13 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
case 19 | DN w/o DPP-4ib | female | 140/80 | 0.36 | 137.1 | 2.6 | 267 | 12.7 | 3.2 | unknown | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
case 20 | DN with DPP-4i | male | 162/66 | 2.21 | 24.2 | 2.4 | 274 | 7.1 | 4.5 | 27 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 |
case 21 | DN with DPP-4i | male | 138/76 | 2.00 | 32.7 | 2.4 | 245 | 9.3 | 6.3 | 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
case 22 | DN with DPP-4i | male | 130/70 | 2.00 | 29.2 | 3.9 | 150 | 6.4 | 7.3 | 3 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
case 23 | DN with DPP-4i | male | 138/68 | 1.82 | 29.3 | 4.4 | 162 | 6.0 | 0.7 | 30 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
case 24 | DN with DPP-4i | male | 152/78 | 0.76 | 74.8 | 3.9 | 184 | 7.0 | 0.2 | 10 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
case 25 | DN with DPP-4ib | male | 132/68 | 2.07 | 27.9 | 3.7 | 127 | 6.8 | 3.3 | 5 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
case 26 | DN with DPP-4ib | male | 112/82 | 0.58 | 106.0 | 4.1 | 564 | 8.1 | 2.8 | 6 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 |
case 27 | DN with DPP-4ib | male | 148/64 | 1.46 | 32.9 | 2.3 | 478 | 8.5 | 13.5 | 12 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |